[go: up one dir, main page]

CL2013003133A1 - Kit farmacéutico que comprende un anticuerpo monoclonal mab antagonista que se une específicamente a egfr humano, y comprende un inhibidor irreversible de tirosina quinasa - Google Patents

Kit farmacéutico que comprende un anticuerpo monoclonal mab antagonista que se une específicamente a egfr humano, y comprende un inhibidor irreversible de tirosina quinasa

Info

Publication number
CL2013003133A1
CL2013003133A1 CL2013003133A CL2013003133A CL2013003133A1 CL 2013003133 A1 CL2013003133 A1 CL 2013003133A1 CL 2013003133 A CL2013003133 A CL 2013003133A CL 2013003133 A CL2013003133 A CL 2013003133A CL 2013003133 A1 CL2013003133 A1 CL 2013003133A1
Authority
CL
Chile
Prior art keywords
monoclonal antibody
specifically binds
tyrosine kinase
kinase inhibitor
pharmaceutical kit
Prior art date
Application number
CL2013003133A
Other languages
English (en)
Inventor
Flavio Solca
Louis Denis
Robert Lorence
Mehdi Shahidi
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46085062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003133(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2013003133A1 publication Critical patent/CL2013003133A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2013003133A 2011-05-17 2013-10-29 Kit farmacéutico que comprende un anticuerpo monoclonal mab antagonista que se une específicamente a egfr humano, y comprende un inhibidor irreversible de tirosina quinasa CL2013003133A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11166446 2011-05-17

Publications (1)

Publication Number Publication Date
CL2013003133A1 true CL2013003133A1 (es) 2014-07-11

Family

ID=46085062

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003133A CL2013003133A1 (es) 2011-05-17 2013-10-29 Kit farmacéutico que comprende un anticuerpo monoclonal mab antagonista que se une específicamente a egfr humano, y comprende un inhibidor irreversible de tirosina quinasa

Country Status (14)

Country Link
US (4) US8828391B2 (es)
EP (1) EP2712320B1 (es)
JP (2) JP6228111B2 (es)
KR (1) KR20140031903A (es)
CN (1) CN103533961B (es)
AU (1) AU2012257727B2 (es)
BR (1) BR112013029385A2 (es)
CA (1) CA2836396A1 (es)
CL (1) CL2013003133A1 (es)
EA (1) EA201301270A1 (es)
IL (1) IL228741A (es)
MX (1) MX2013013018A (es)
PH (1) PH12013502333A1 (es)
WO (1) WO2012156437A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2833706C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
PL1948180T3 (pl) * 2005-11-11 2013-09-30 Boehringer Ingelheim Int Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
LT2451445T (lt) 2009-07-06 2019-06-25 Boehringer Ingelheim International Gmbh Bibw2992, jo druskų ir kietų farmacinių kompozicijų, apimančių šį aktyvųjį ingredientą, džiovinimo būdas
MX340536B (es) 2011-07-06 2016-07-13 Sykehuset Sorlandet Hf Terapia direccionada al receptor del factor de crecimiento epidermico (egfr).
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
WO2013106792A1 (en) 2012-01-13 2013-07-18 Acea Biosciences Inc. Heterocyclic compounds and uses as anticancer agents.
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
MX2014014829A (es) * 2012-06-07 2015-02-12 Hoffmann La Roche Anticuerpos autoinmunes.
US20150320861A1 (en) 2012-12-21 2015-11-12 Sykehuset Sørlandet Hf Egfr targeted therapy of neurological disorders and pain
CN112592334B (zh) 2013-07-11 2023-10-27 艾森医药公司 嘧啶衍生物作为激酶抑制剂
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
WO2015112705A2 (en) * 2014-01-24 2015-07-30 Clovis Oncology, Inc. Therapeutic combinations for treating cancer
US9211314B2 (en) * 2014-04-04 2015-12-15 Biodesix, Inc. Treatment selection for lung cancer patients using mass spectrum of blood-based sample
CN104174031B (zh) * 2014-07-31 2017-06-13 清华大学 逆转肿瘤多药耐药的基因组合物‑h‑R3/PAMAM G5/GCS siRNA及其应用
CN104189920B (zh) * 2014-07-31 2017-02-01 清华大学 逆转肿瘤多药耐药的基因组合物h‑R3/PAMAM G5/MDR1 siRNA及其应用
CN107427515B (zh) * 2014-12-03 2021-11-16 奥克兰联合服务有限公司 用于治疗癌症的激酶抑制剂前药
US10982287B2 (en) * 2015-01-06 2021-04-20 The Johns Hopkins University Response to EGFR blockade
EP3288963B1 (en) * 2015-05-01 2020-12-23 Wo, Andrew Man Chung Pink1 c-terminal domain polypeptide and methods using the same in cancer treatment
US20190358320A1 (en) * 2015-05-12 2019-11-28 In3Bio Ltd. Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
US20160333087A1 (en) * 2015-05-12 2016-11-17 Bioven 3 Limited Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
EP3359159B1 (en) 2015-10-09 2023-06-07 ACEA Therapeutics, Inc. Pharmaceutical compositions of a pyrrolopyrimidine kinase inhibitor, and methods of making same
CN107684624A (zh) * 2016-08-05 2018-02-13 江苏嵌合体生物技术有限公司 表皮生长因子受体相关癌症的组合治疗
TWI808958B (zh) * 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
EP3606925A1 (en) 2017-04-07 2020-02-12 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
EP3641818A1 (en) * 2017-06-23 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for preventing or treating cancer resistance to egfr inhibition
US12343428B2 (en) 2017-11-03 2025-07-01 University Of Virginia Patent Foundation Compositions and methods for cancer treatment
EP3773551B1 (en) * 2018-03-27 2024-10-16 Board of Regents, The University of Texas System Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
WO2020005934A1 (en) * 2018-06-25 2020-01-02 Spectrum Pharmaceuticals, Inc. Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
CN112384528A (zh) * 2018-06-25 2021-02-19 光谱制药有限公司 波齐替尼与细胞毒剂和/或其他分子靶向剂的组合物及其用途
EP3599284A1 (en) 2018-07-27 2020-01-29 Bio-Id Diagnostic Inc. Simultaneous detection of multiple nucleic acid templates using modified primers
US12257245B2 (en) 2018-08-07 2025-03-25 In3Bio Ltd. Methods and compositions for inhibition of EGF/EGFR pathway in combination with anaplastic lymphoma kinase inhibitors
KR20210144844A (ko) * 2019-03-29 2021-11-30 아스트라제네카 아베 비-소세포 폐암의 치료에 사용하기 위한 오시머티닙
WO2021142408A1 (en) 2020-01-11 2021-07-15 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Estrogen metabolite levels and cancer driver gene mutations in lung cancer risk stratification and treatment
KR20230154793A (ko) * 2020-12-11 2023-11-09 에라스카, 아이엔씨. 암 치료를 위한 병용 요법
CN112300284B (zh) * 2020-12-29 2021-04-06 慈达(广州)生物技术有限公司 核酸筛选结合抗体检测用于癌症检测中的用途及其制备的试剂盒
CN113234832B (zh) * 2021-06-30 2022-06-03 深圳市狂风生命科技有限公司 人类egfr基因错义突变分子标志物及其在预测靶向抑制剂抗药性中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
MXPA01012899A (es) 1999-06-21 2002-07-30 Boehringer Ingelheim Pharma Heterociclos biciclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion.
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US20030225079A1 (en) 2002-05-11 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
DE10307165A1 (de) 2003-02-20 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
SI1746999T1 (sl) 2004-05-06 2012-01-31 Warner Lambert Co 4-fenilamino-kinazolin-6-il-amidi
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
PL1948180T3 (pl) 2005-11-11 2013-09-30 Boehringer Ingelheim Int Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
CA2833706C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
SI1981863T1 (sl) 2006-01-26 2013-01-31 Boehringer Ingelheim International Gmbh Postopek za pripravo aminokrotonilamino-substituiranih kinazolinskih derivatov
RU2492864C2 (ru) 2006-09-18 2013-09-20 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения рака, несущего мутации egfr
WO2008091701A2 (en) * 2007-01-25 2008-07-31 Dana-Farber Cancer Institute Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
EP2190878A1 (en) * 2007-09-06 2010-06-02 Genmab A/S Novel methods and antibodies for treating cancer
PE20100252A1 (es) 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
EP2387401A1 (en) 2009-01-14 2011-11-23 Boehringer Ingelheim International GmbH Method for treating colorectal cancer
WO2010085845A1 (en) 2009-01-28 2010-08-05 The University Of Queensland Cancer therapy and/or diagnosis
EP2440559B1 (en) * 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
LT2451445T (lt) 2009-07-06 2019-06-25 Boehringer Ingelheim International Gmbh Bibw2992, jo druskų ir kietų farmacinių kompozicijų, apimančių šį aktyvųjį ingredientą, džiovinimo būdas
EP3527585B1 (en) * 2009-11-03 2022-02-16 City of Hope Truncated epiderimal growth factor receptor (egfrt) for transduced t cell selection
JP2013512882A (ja) 2009-12-07 2013-04-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング トリプルネガティブ乳癌の治療に使用するｂｉｂｗ２９９２
KR101217526B1 (ko) 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
EP2696870A1 (en) * 2011-04-11 2014-02-19 Abbvie Inc. Parp inhibitors for the treatment of cipn

Also Published As

Publication number Publication date
US20140341926A1 (en) 2014-11-20
JP6282296B2 (ja) 2018-02-21
JP2016065109A (ja) 2016-04-28
AU2012257727A1 (en) 2013-10-24
KR20140031903A (ko) 2014-03-13
CN103533961B (zh) 2016-08-03
EA201301270A1 (ru) 2014-05-30
US8828391B2 (en) 2014-09-09
PH12013502333A1 (en) 2014-01-06
CN103533961A (zh) 2014-01-22
MX2013013018A (es) 2014-01-31
US20120294867A1 (en) 2012-11-22
JP2014513706A (ja) 2014-06-05
EP2712320A1 (en) 2014-04-02
AU2012257727B2 (en) 2016-09-01
IL228741A0 (en) 2013-12-31
CA2836396A1 (en) 2012-11-22
US20160101175A1 (en) 2016-04-14
NZ616183A (en) 2015-09-25
BR112013029385A2 (pt) 2017-01-31
JP6228111B2 (ja) 2017-11-08
EP2712320B1 (en) 2019-10-02
US20170312360A1 (en) 2017-11-02
IL228741A (en) 2016-08-31
WO2012156437A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
CL2013003133A1 (es) Kit farmacéutico que comprende un anticuerpo monoclonal mab antagonista que se une específicamente a egfr humano, y comprende un inhibidor irreversible de tirosina quinasa
CY2020045I2 (el) Anti-pd-l1 αντισωματα και χρησεις αυτων
CL2014002955A1 (es) Antagonista anticuerpo que se une a st2l y métodos de uso
LTC2579894I2 (lt) CGRP antikūnai
CL2014000574A1 (es) Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.
PL3219729T3 (pl) Przeciwciało monoklonalne przeciwko IL-31
BR112014028600A2 (pt) formulações de anticorpo monoclonal de alta concentração
IL254004A0 (en) Monoclonal antibodies to progastrin and their uses
IL236517A0 (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
CO7020875A2 (es) Anticuerpos humanizados que reconocen la alfa-sinucleina
IL221408B (en) Monoclonal antibodies against c-met
EP2324359A4 (en) MONOCLONAL ANTIBODY STRO-4
IL229618B (en) Isolated antibody that binds fcrn
SMT201400184B (it) Anticorpi monoclonali che legano b7h6 e loro usi
PL2734552T3 (pl) Hamujące monoklonalne przeciwciała skierowane przeciwko czynnikowi xii/xiia i ich zastosowanie
PL3088421T3 (pl) Przeciwciała monoklonalne do zastosowania w diagnostyce i leczeniu nowotworów i choroby autoimmunologicznej
EP2731612A4 (en) BRUTON TYROSINE KINASE HEMMER
PL3342786T3 (pl) Przeciwciało przeciwko dll3
BR112013029620A2 (pt) inibidores de tirosina quinase de bruton
EP2636736A4 (en) NOVEL ANTI-DR5 ANTIBODY
BR112015003938A2 (pt) métodos de produção de polipeptídeos, de produção de aglutinantes multiespecíficos, de seleção de aglutinantes multiespecíficos, de seleção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação farmcêutica e uso de anticorpo biespecífico
EP2859114A4 (en) PROTEINS FOR BINDING ANTAGONISTIC ANTIGENS WITH TWO RECEPTORS AND USES THEREOF
EP2483416A4 (en) MONOCLONAL ANTIBODIES
EP2593475A4 (en) MONOCLONAL ANTIBODY AGAINST ADDL AND APPLICATIONS THEREOF
EP2694544A4 (en) MONOCLONAL ANTIBODIES AGAINST INHIBITOR TISSUE FACTOR PATHWAY (TFPI)